Vaxart (VXRT) Stock Price, News & Analysis

Company Overview

Vaxart, Inc. is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development. Among these are an oral tablet for norovirus, an oral influenza vaccine, and VXA-CoV2-1, an oral COVID-19 vaccine candidate. Vaxart has reported data from Phase I and Phase II clinical trials demonstrating favorable safety profiles and immune responses that support further clinical evaluation. In addition to its lead programs, Vaxart is exploring applications of its platform for prophylactic and therapeutic vaccines against other respiratory and enteric pathogens.

Headquartered in South San Francisco, California, Vaxart collaborates with academic institutions and government agencies to advance its oral vaccine technology. The company’s management team brings together experienced professionals in vaccine R&D, regulatory affairs, and commercial strategy, guiding Vaxart through clinical and regulatory milestones. By focusing on ease of administration and global distribution, Vaxart seeks to address unmet needs in vaccine access and public health preparedness.

Key Stats

• Today's Range: $0.64 to $0.71
• 50-Day Range: $0.60 to $0.78
• 52-Week Range: $0.26 to $0.84
• Volume: 496,596 shs
• Average Volume: 465,706 shs
• Market Capitalization: $156.02 million
• P/E Ratio: 4.30
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Vaxart Stock Analysis - MarketRank™

Vaxart scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Vaxart.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Vaxart is 4.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.03.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vaxart is 4.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.01.

Price to Book Value per Share Ratio

Vaxart has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.24% of the float of Vaxart has been sold short.

Short Interest Ratio / Days to Cover

Vaxart has a short interest ratio ("days to cover") of 3.55, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vaxart has recently decreased by 3.95%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vaxart does not currently pay a dividend.

Dividend Growth

Vaxart does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.46

News Sentiment

Vaxart has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Vaxart this week, compared to 1 article on an average week.

Search Interest

14 people have searched for VXRT on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Vaxart to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vaxart insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.80% of the stock of Vaxart is held by insiders.

Percentage Held by Institutions

18.05% of the stock of Vaxart is held by institutions.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 5/25/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:VXRT
• Previous Symbol: NASDAQ:NABI
• CIK: 72444
• Web: www.vaxart.com
• Phone: (650) 550-3500
• Fax: 650-871-8580
• Employees: 120
• Year Founded: 2004

Profitability

• EPS (Trailing Twelve Months): $0.15
• Trailing P/E Ratio: 4.30
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $16.33 million
• Net Margins: 14.51%
• Pretax Margin: 14.67%
• Return on Equity: 61.43%
• Return on Assets: 20.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.71
• Quick Ratio: 1.71

Sales & Book Value

• Annual Sales: $237.26 million
• Price / Sales: 0.66
• Cash Flow: $0.10 per share
• Price / Cash Flow: 6.30
• Book Value: $0.39 per share
• Price / Book: 1.65

Miscellaneous

• Outstanding Shares: 241,970,000
• Free Float: 235,199,000
• Market Cap: $156.02 million
• Optionable: No Data
• Beta: 1.18